VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

PURPOSE: Despite promising activity in hematopoietic malignancies, efficacy of the B-cell lymphoma 2 (BCL2) inhibitor venetoclax in solid tumors is unknown. We report the prespecified VERONICA primary results, a randomized phase II clinical trial evaluating venetoclax and fulvestrant in estrogen rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindeman, Geoffrey J., Fernando, Tharu M., Bowen, Rebecca, Jerzak, Katarzyna J., Song, Xinni, Decker, Thomas, Boyle, Frances, McCune, Steve, Armstrong, Anne, Shannon, Catherine, Bertelli, Gianfilippo, Chang, Ching-Wei, Desai, Rupal, Gupta, Kushagra, Wilson, Timothy R., Flechais, Aulde, Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662928/
https://www.ncbi.nlm.nih.gov/pubmed/35583555
http://dx.doi.org/10.1158/1078-0432.CCR-21-3811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662928/
https://www.ncbi.nlm.nih.gov/pubmed/35583555
http://dx.doi.org/10.1158/1078-0432.CCR-21-3811

Ejemplares similares